Artemis Therapeutics Inc. – OTC:ATMS

Artemis Therapeutics stock price today

$1.29
+0.79
+159.04%
Financial Health
0
1
2
3
4
5
6
7
8
9

Artemis Therapeutics stock price monthly change

+66.61%
month

Artemis Therapeutics stock price quarterly change

-66.58%
quarter

Artemis Therapeutics stock price yearly change

-84.44%
year

Artemis Therapeutics key metrics

Market Cap
 127.15M
Enterprise value
 9.32M
P/E
 -17.31
EV/Sales
 79.01
EV/EBITDA
 -38.63
Price/Sales
 76.72
Price/Book
 -13.92
PEG ratio
 -0.47
EPS
 N/A
Revenue
 671K
EBITDA
 -1.17M
Income
 N/A
Revenue Q/Q
 49.15%
Revenue Y/Y
 274.26%
Profit margin
 -209.32%
Oper. margin
 -411.02%
Gross margin
 96.61%
EBIT margin
 -411.02%
EBITDA margin
 -175.26%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Artemis Therapeutics stock price history

Artemis Therapeutics stock forecast

Artemis Therapeutics financial statements

Profit Margin

Artemis Therapeutics Inc. (OTC:ATMS): Profit margin
Dec 2022 116K -518K -446.55%
Mar 2023 173K -234K -135.26%
Jun 2023 206K 15K 7.28%
Sep 2023 176K 0
ATMS income statement history

Debt to Assets

Artemis Therapeutics Inc. (OTC:ATMS): Debt to assets
Dec 2022 265000 1.29M 487.17%
Mar 2023 291000 1.45M 500%
Jun 2023 0 0
Sep 2023 72000 1.59M 2209.72%
ATMS balance sheet history

Cash Flow

Artemis Therapeutics Inc. (OTC:ATMS): Cash Flow
Jun 2022 -294.29K 0 -10.74K
Sep 2022 -55.70K -8.36K -256
Dec 2022 -41K -17.63K 11K
Mar 2023 -96K 0 150K
ATMS cash flow history

Artemis Therapeutics alternative data

Artemis Therapeutics
Employees

Artemis Therapeutics Inc. (OTC:ATMS): Employee count
Aug 2023 4
Sep 2023 4
Oct 2023 4
Nov 2023 4
Dec 2023 4
Jan 2024 4
Feb 2024 4
Mar 2024 4
Apr 2024 4
May 2024 4
Jun 2024 4
Jul 2024 4

Artemis Therapeutics other data

Artemis Therapeutics
Insider Trading

Artemis Therapeutics Inc. (OTC:ATMS): Insider trades (number of shares)
Period Buy Sel
Dec 2018 0 182
Transaction Date Insider Security Shares Price per share Total value Source
Sale
PELEG GADI director
 Common Stock 182 $0.26 $47
Purchase
CULLEY BRIAN M officer: Chief Executive Officer
 Warrant 12,500 $2 $25,000
Purchase
CULLEY BRIAN M officer: Chief Executive Officer
 Common Stock 25,000 N/A N/A
Option
WOLF DANA officer: Chief Scientific Officer
 Common Stock 35,202 $0.01 $352
Option
WOLF DANA officer: Chief Scientific Officer
 Stock Option (Right to Buy) 35,202 $0.01 $352
Sale
SCHOENHEIMER PIERRE LUCIEN director
 Common Stock 10,000 $0.18 $1,800
Sale
SCHOENHEIMER PIERRE LUCIEN director
 Common Stock 19,000 $0.15 $2,850
Sale
SCHOENHEIMER PIERRE LUCIEN director
 Common Stock 45,000 $0.15 $6,615
Purchase
PELEG GADI director
 Common Stock 3,200,000 $0.13 $400,000
Purchase
SCHOENHEIMER PIERRE LUCIEN director
 Common Stock 2,000,000 $0.13 $250,000
ATMS insider trading transactions

Frequently Asked Questions (FAQ)

  • What's the price of Artemis Therapeutics stock today?

    One share of Artemis Therapeutics stock can currently be purchased for approximately $1.29.

  • When is Artemis Therapeutics's next earnings date?

    Unfortunately, Artemis Therapeutics's (ATMS) next earnings date is currently unknown.

  • Does Artemis Therapeutics pay dividends?

    No, Artemis Therapeutics does not pay dividends.

  • How much money does Artemis Therapeutics make?

    Artemis Therapeutics has a market capitalization of 127.15M.

  • What is Artemis Therapeutics's stock symbol?

    Artemis Therapeutics Inc. is traded on the OTC under the ticker symbol "ATMS".

  • What is Artemis Therapeutics's primary industry?

    Company operates in the Financial Services sector and Shell Companies industry.

  • How do i buy shares of Artemis Therapeutics?

    Shares of Artemis Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Artemis Therapeutics's key executives?

    Artemis Therapeutics's management team includes the following people:

    • Mr. Chanan Morris Chief Financial Officer(age: 59, pay: $42,000)

  • When Artemis Therapeutics went public?

    Artemis Therapeutics Inc. is publicly traded company for more then 27 years since IPO on 17 Feb 1998.

  • What is Artemis Therapeutics's official website?

    The official website for Artemis Therapeutics is bmanuka.co.il.

  • Where are Artemis Therapeutics's headquarters?

    Artemis Therapeutics is headquartered at 18 East 16th Street, New York, NY.

  • How can i contact Artemis Therapeutics?

    Artemis Therapeutics's mailing address is 18 East 16th Street, New York, NY and company can be reached via phone at +64 6 233 1454.

Artemis Therapeutics company profile:

Artemis Therapeutics Inc.

bmanuka.co.il
Exchange:

OTC

Full time employees:

0

Industry:

Shell Companies

Sector:

Financial Services

Artemis Therapeutics Inc., a beauty company, develops and distributes skincare products in Israel. The company offers face serum with manuka honey and bee venom, face serum with enhanced vitamin C, day cream, night nourishing cream with manuka honey and nee venom, eye cream with manuka honey and bee venom, and face cleanser gel. It also distributes manuka honey imported from New Zealand. The company was incorporated in 2020 and is based in Ramat Gan, Israel.

+64 6 233 1454
18 East 16th Street
New York, NY 4959507

CIK: 0001062128
:
: